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Background: Low serum amylase is likely to be associated with obesity and metabolic abnormalities, which are
often accompanied by impaired insulin action. However, it is unclear whether low serum amylase is associated with
impaired insulin action in clinical settings. Therefore, we investigated the associations of low serum amylase with
plasma insulin levels, and obesity-related parameters, including leptin.
Research design and methods: We measured serum amylase, plasma insulin, obesity-related parameters such as
leptin, cardiometabolic risk factors, and anthropometric parameters in a cross-sectional study of 54 asymptomatic
subjects (mean age 48.6 ± 7.6 years) who were not being treated for diabetes.
Results: Body mass index (BMI) and plasma glucose at 120 min after a 75-g oral glucose tolerance test (OGTT) were
significantly higher in subjects with low serum amylase (< 60 IU/l, n = 21) than in those with normal-to-high serum
amylase (n = 33) (P= 0.04 and P= 0.004, respectively). In univariate correlation analysis, serum amylase was
significantly correlated with BMI alone (r= –0.39, P= 0.004). By contrast, multivariate logistic analysis showed that
each 1-SD increase in quantitative insulin sensitivity check index, and each 1-SD decrease in plasma insulin OGTT at
0 and 60 min, homeostasis model assessment of insulin resistance (HOMA)-R, and HOMA-β were significantly
associated with low serum amylase, particularly after adjusting for BMI. When subjects were divided into three
groups according to HOMA-R, serum amylase levels were significantly lower in subjects with HOMA-R> 2.5 (n = 23)
compared with subjects with HOMA-R 1.6–2.5 (n = 10) (61.1 ± 13.6 U/ml versus 76.9 ± 20.5 U/ml, Bonferroni test,
P= 0.02), but not compared with subjects with HOMA-R<1.6 (n = 21; 62.7 ± 17.6 U/ml). Similar trends were observed
when subjects were divided according to plasma leptin and fasting plasma insulin levels.
Conclusions: These results suggest that after adjusting for BMI, low serum amylase is associated with decreased
basal insulin levels and insulin secretion, as well as high insulin resistance. The nature of these associations remains
to be elucidated in further studies.
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For many years, low serum amylase was thought to reflect
diffuse pancreatic destruction secondary to advanced
pancreatic diseases, such as chronic pancreatitis [1, 2].
Recently, several large clinical studies have shown that
low serum amylase is also associated with metabolic syn-
drome and diabetes [3, 4]. However, the mechanisms
underlying these associations remain unclear. In pre-
vious epidemiological studies [3, 5], we observed a
marked negative association between serum amylase
and body mass index (BMI). Consequently, we
hypothesized that high BMI (i.e., obesity) is the most
critical factor that is inversely correlated with serum
amylase, and that insulin inactivity is a putative sec-
ondary factor that regulates the observed association.
In our previous sub-analysis [5], we found that the
relationship between serum amylase levels and gly-
cated hemoglobin (HbA1c) was rather complicated
(not a simple linear relationship), particularly in indi-
viduals with normal or mildly impaired glucose me-
tabolism. Unfortunately, plasma insulin and obesity-
related parameters, such as leptin and tumor necrosis
factor (TNF) α, were not measured in the earlier
studies. Therefore, we were unable to determine whether
impaired insulin action, particularly insulin resistance,
could mediate the associations between low serum amyl-
ase and diabetes and metabolic syndrome.
In this cross-sectional study of asymptomatic middle-
aged subjects without advanced diabetes, plasma insulin
and obesity-related parameters were measured along with
other cardiometabolic risk factors. Here, we report latent
associations between low serum amylase and plasma insu-
lin, insulin resistance, and obesity-related parameters. Lep-
tin, an adipokine that regulates energy balance through a
wide range of systemic functions, is associated with obesity
and insulin resistance [6, 7]. Additionally, TNFα, a proin-
flammatory adipokine, was proposed as a link between
obesity and insulin resistance [8, 9]. Therefore, we also
examined the associations between low serum amylase
and these adipokines in this study.
Methods
Subjects
This study was based on a composite research pro-
gram that was conducted in collaboration with
Saitama Medical Center, Jichi Medical University
School of Medicine, Saitama, Japan, and the Social In-
surance Omiya General Hospital, Saitama, Japan. As
in the previous study by Aoki et al. [10], we recruited
subjects who visited Social Insurance General Omiya
Hospital between October 2008 and December 2009,
for annual metabolic health checkups. Exclusion cri-
teria were as follows: taking any antihypertensive or
hypoglycemic agent, diuretic, lipid-lowering agent orinsulin; and history of malignancy, liver disease or
kidney disease. Subjects lacking data for serum amyl-
ase and responses to the lifestyle questionnaire were
also excluded. Consequently, 44 men and 10 women
were included in the current analysis. The study was
approved by the Ethics Committee at Jichi Medical
University, Tochigi, Japan. All subjects were informed
about the study and provided written consent. An-
thropometric measurements and laboratory tests were
conducted using standard methods as previously described
[10]. Blood samples were obtained in the early morning
after an overnight fast. All of the subjects then underwent
a 75-g oral glucose tolerance test (OGTT), and blood sam-
ples were obtained at 60 and 120 min to measure plasma
glucose (PG) and plasma insulin (PI) concentrations. Insu-
lin, leptin, and TNFα were measured using commercially
available enzyme-linked immunosorbent assays (insulin:
Yanaihara Institute Inc., Shizuoka, Japan; leptin: R&D Sys-
tems, Minneapolis, MN, USA; TNFα: Invitrogen Corp,
Carlsbad, CA, USA).
Homeostasis model assessment of insulin resistant
(HOMA-R), an index of insulin resistance, quantitative in-
sulin sensitivity check index (QUICKI), and HOMA-β, an
index of the insulin secretion capacity in the basal state,
were calculated using the following equations:
HOMA
R
¼ FPG FPIð Þ=405
QUICKI ¼ 1= log FPIð Þ þ log FPGð Þ½ 
HOMA
β
¼ 360 FPIð Þ= FPG 63ð Þ
where FPG= fasting plasma glucose and FPI= fasting
plasma insulin.
Serum amylase levels were measured using an enzymatic
method (L-type Amylase assay; Wako, Tokyo, Japan) with a
normal range of 41–112 IU/l, a detection limit of 1.7 IU/l,
and a run-to-run coefficient of variation< 5.0%. PG was
measured by the glucose oxidase method. HbA1c was mea-
sured in Japan Diabetes Society (JDS)-HbA1c units by high-
performance liquid chromatography. HbA1c was converted
to National Glycohemoglobin Standardization Program
(NGSP) levels by the formula HbA1c (%) (NGSP)=HbA1c
(JDS) (%)+0.4%, considering the relational expression of
HbA1c (JDS) (%) measured by the previous Japanese stand-
ard substance and measurement methods [11]. Since serum
amylase levels can be affected by kidney function because of
its excretion from the kidney [12, 13], the estimated
glomerular filtration rate (eGFR) was included as a
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eGFR was calculated using the Modification Diet in
Renal Disease study equation for Japanese subjects
[14], as follows:
eGFR ml=min=1:73 m2
  ¼ 194 serumCr1:094
 age0:287 iffemaleð Þ
 0:739
where Cr = serum creatinine concentration (mg/dl).
Statistical analysis
All data are expressed as means ± SD or median (inter-
quartile range). Subjects were dichotomized according to
the serum amylase level as either low (< 60 IU/l, n = 21)
or high (≥ 60 IU/l, n = 33), because the 25th percentile of
serum amylase level was approximately 60.0 IU/l in our
large epidemiological study [3], in which serum amylase
concentration was measured using the same methods at
our hospital. Since the present study involved a small
number of subjects, we used the earlier data to esti-
mate the threshold for low serum amylase. P-values
for continuous variables and categorical variables
were determined using the Mann–Whitney test and
the χ2-test with Yates’s correction, respectively. Be-
cause the distribution of triglyceride, PI at 0, 60, and
120 min, HOMA-R, HOMA-β, leptin, and TNF were
highly skewed, these values were log-transformed be-
fore analysis. To examine the univariate linear corre-
lations among serum amylase and variables associated
with insulin resistance and glucose metabolism, Pear-
son’s correlation coefficients were determined. Mul-
tiple stepwise regression analysis was conducted to
identify independent parameters that significantly
explained serum amylase levels. Categorical dichot-
omous parameters were labeled as 0 or 1. In multi-
variate logistic regression models, the odds ratios for
low serum amylase were calculated for each 1-SD in-
crease/decrease in the clinical variables. To examine
the effects of insulin resistance, subjects were divided
into three groups according to HOMA-R, leptin
levels, and PI during OGTTs. Normal, moderate and
high HOMA-R were defined as< 1.6, 1.6–2.5, and
> 2.5, respectively, according to studies by Taniguchi
et al. [15] and the criteria proposed by the Japan Dia-
betes Society 2010. The numbers of subjects in the
three groups (normal, moderate, high) of leptin levels
and PI during OGTTs were set to be similar to those
in the normal, moderate, and high HOMA-R groups,
because the thresholds for these values have not been
established. Serum amylase was examined by two-way
analysis of variance (ANOVA) with HOMA-R, leptin,
and PI during OGTTs as one factor, and obesity (i.e.,
BMI) as the second factor. Significant differences inserum amylase between groups were determined
using Bonferroni’s post hoc test and P<0.017 was
considered statistically significant. Statistical analysis
was performed using SPSS software version 18.0
(SPSS-IBM Chicago, IL, USA). Values of P<0.05 were
considered statistically significant, except in the post
hoc tests following ANOVA.
Results
The mean and median values of most clinical parameters
were within the normal ranges (Table 1). Five subjects
were suspected of having type 2 diabetes because their
PG at 120 min was ≥ 200 mg/dl, even though FPG
was<126 mg/dl. BMI and PG at 120 min were signifi-
cantly higher in subjects with low serum amylase than in
those with normal to high serum amylase. Table 2 shows
the univariate linear correlation coefficients between
serum amylase and variables associated with insulin re-
sistance and glucose metabolism. Serum amylase was
significantly correlated with BMI, but no other variable.
HOMA-R was very closely correlated with FPI (r= 0.997,
P<0.001), but showed weaker correlation with FPG
(r= 0.53, P<0.001, data not shown). Stepwise regression
analysis revealed that of the independent clinical vari-
ables listed in Table 1, BMI and PI at 60 min (β coeffi-
cient =–0.56 and 0.38, respectively, adjusted R2 = 0.26,
data not shown) were significantly associated with serum
amylase. In multivariate logistic analysis, each 1-SD in-
crease in BMI was significantly associated with low
serum amylase, even after controlling for confounding
factors (Table 3). By contrast, each 1-SD increase in
QUICKI, and 1-SD decreases in PI at 0 and 60 min,
HOMA-R, and HOMA-β was significantly associated
with low serum amylase, particularly after adjusting for
BMI (Model 3). The significant association between low
serum amylase and PG at 120 min disappeared after
adjusting for BMI. In all analyses adjusted for BMI
(Model 3), each 1-SD increase in BMI was significantly
associated with low serum amylase (data not shown).
When subjects were divided into three groups accord-
ing to HOMA-R, the serum amylase levels in subjects
with high HOMA-R were significantly lower than those
in subjects with moderate HOMA-R (Bonferroni test,
P= 0.014) (Figure 1A). When subjects were further
divided into obese (BMI ≥ 25.0 kg/m2, n = 22) and lean
(BMI<25.0 kg/m2, n = 32) groups, similar nonlinear
trends were observed in both groups, which was of
borderline significance in the obese group (two-way
ANOVA, P= 0.05, Figure 1B). As shown in Figure 1C
and D, no significant difference was observed in HOMA-
R and leptin between the lean and obese groups, except
for HOMA-R in the high HOMA-R group.
Similarly, as shown in Figure 2A, serum amylase
levels in subjects with high leptin (> 35 pg/ml,









n 21 33 –
Age 47.1 ± 7.3 49.6 ± 7.8 0.22
Men, n (%) 17 (81.0) 27 (81.8) 0.93
Body mass
index (kg/m2)
25.5 ± 3.9 23.4 ± 2.6 0.04
Systolic blood
pressure (mmHg)
119 ± 18.5 118 ± 15.0 0.88
Diastolic blood
pressure (mmHg)
71.9 ± 11.6 73.8 ± 11.5 0.54
Triglyceride (mg/dl) 117 (88-184) 92 (76-125) 0.17
HDL-cholesterol
(mg/dl)
55.9 ± 16.1 54.8 ± 10.7 0.96
Creatinine (mg/dl) 0.8 ± 0.2 0.8 ± 0.1 0.93
eGFR
(ml/min/1.73 m2)
84.8 ± 16.9 80.5 ± 11.1 0.56
Amylase (IU/l) 49.4 ± 7.6 74.6 ± 14.1 —
(range) (32–59) (60–121)
HbA1c (%) (NGSP) 5.7 ± 0.3 5.6 ± 0.3 0.47
FPG (mg/dl) 102 ± 11 98± 7.6 0.32
PG at 60 min (mg/dl)* 144 ± 40 138 ± 33 0.56
PG at 120 min (mg/dl)* 151 ± 44 119 ± 35 0.004
FPI (μU/ml) 6.0 (3.6–14.9) 10.3 (5.1–13.1) 0.30
PI at 60 min (μU/ml)* 32.2 (18.7–62.1) 55.3 (41.7–86.3) 0.06
PI at 120 min
(μU/ml)*
47.3 (31.6–102) 45.4 (29.0–65.6) 0.67
HOMA-R 1.5 (0.9–3.9) 2.3 (1.2–3.4) 0.45
QUICKI 0.38 ± 0.10 0.34 ± 0.04 0.45
HOMA-β 57.6 (34–125) 104 (54-138) 0.10
Leptin (pg/ml) 37.3 (18–55) 27.9 (18–43) 0.40
TNFα (pg/ml) 0.69 (0.5–1.1) 0.56 (0.5–0.7) 0.08
Type 2 diabetes† 4 1 0.13
Current
smokers, n (%)
6 (28.6) 11 (33.3) 0.95
Everyday alcohol
drinkers, n (%)
10 (47.6) 9 (27.3) 0.19
Regular exerciser, n (%) 3 (14.3) 7 (21.2) 0.78
Data are means ± SD or medians (interquartile range) for highly skewed
variables.
Continuous variables and categorical valuables were compared using the
Mann–Whitney test and χ2-test, respectively.
*Measured during a 75-g OGTT.
†Five subjects were suspected of having type 2 diabetes because PG at
120 min was ≥ 200 mg/dl.
eGFR: estimated glomerular filtration rate; FPG: fasting plasma glucose; FPI:
fasting plasma insulin; HDL-C: high-density lipoprotein; HOMA: homeostasis
model assessment; OGTT: oral glucose tolerance test; NGSP; National
Glycohemoglobin Standardization Program; PG: plasma glucose; PI: plasma
insulin; QUICKI: quantitative insulin sensitivity check index; regular exerciser:
subjects who exercise over 30 minutes at least twice per week; TNF α: tumor
necrosis factor α.
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with moderate leptin (25–35 pg/ml, n = 12; Bonferroni
test, P = 0.013). When subjects were divided into
obese and lean groups, as above, similar trends were
observed in both groups, and was significant in the
obese group (two-way ANOVA, P = 0.02, Figure 2B).
Additionally, serum amylase levels were significantly
lower in obese subjects than in lean subjects among
those with normal or moderate leptin levels, respect-
ively (Mann–Whitney test, both P<0.05). As shown in
Figure 2C and D, there were no significant differences in
HOMA-R and leptin between the lean and obese subjects,
except for HOMA-R in the high leptin group.
Similar trends were also observed when subjects were
divided according to PI at 0 min (data not shown because
of the robust similarities to Figure 1A and B). However,
the trends in the nonlinear relationship were attenuated
when subjects were divided according to PI at 120 min
(Figure 3A), although borderline significant was observed
between lean subjects and obese subjects (two-way
ANOVA, P= 0.06, Figure 3B).Discussion
The present study showed a robust association between
low serum amylase and BMI, as well as latent associa-Table 2 Correlations between serum amylase and BMI









PI at 60 min† 0.13 0.45***
PI at 120 min† –0.09 0.50***
FPG –0.23 0.28
PG at 60 min† –0.16 0.43**
PG at 120 min† –0.27 0.34*
HbA1c –0.13 0.43**
BMI –0.39**
Pearson’s correlation coefficients are shown.
HOMA-R, HOMA-β, leptin, TNFα, FPI, PI at 60 min, and PI at 120 min were log-
transformed before analysis.
*P<0.05, **P<0.01, ***P<0.001.
†Measured during a 75-g OGTT.
BMI: body mass index; FPG: fasting plasma glucose; FPI: fasting plasma insulin;
HOMA: homeostasis model assessment; OGTT: oral glucose tolerance test; PG:
plasma glucose; PI: plasma insulin; QUICKI: quantitative insulin sensitivity check
index; TNFα: tumor necrosis factor α.
Table 3 Associations between clinical variables and low
serum amylase
1-SD* Odds ratio (95% CI) P value
BMI Inc Model 1 2.22 (1.06–4.67) 0.03
Model 2 4.41 (1.36–14.3) 0.01
HbA1c Inc Model 1 1.30 (0.74–2.29) 0.35
Model 2 1.39 (0.75–2.59) 0.29
Model 3 0.80 (0.37–1.75) 0.57
FPG Inc Model 1 1.55 (0.87–2.75) 0.13
Model 2 1.46 (0.72–2.94) 0.29
Model 3 1.12 (0.51–2.49) 0.77
PG at 60 min† Inc Model 1 1.18 (0.68–2.06) 0.55
Model 2 1.10 (0.56–2.18) 0.78
Model 3 0.58 (0.23–1.43) 0.77
PG at 120 min† Inc Model 1 2.45 (1.20–4.99) 0.01
Model 2 2.55 (1.12–5.80) 0.03
Model 3 1.78 (0.74–4.27) 0.20
FPI Dec Model 1 1.53 (0.85–2.76) 0.16
Model 2 2.18 (0.96–4.98) 0.06
Model 3 14.9 (2.45–91.0) 0.003
PI at 60 min† Dec Model 1 1.90 (1.02–3.56) 0.04
Model 2 3.03 (1.27–7.22) 0.01
Model 3 11.6 (2.46–54.5) 0.002
PI at 120 min† Dec Model 1 0.83 (0.47–1.45) 0.51
Model 2 0.79 (0.39–1.62) 0.52
Model 3 1.31 (0.56–3.08) 0.53
HOMA-R Dec Model 1 1.45 (0.81–2.58) 0.21
Model 2 2.03 (0.91–4.53) 0.08
Model 3 11.9 (2.13–66.2) 0.005
QUICKI Inc Model 1 1.73 (0.91–3.29) 0.10
Model 2 2.67 (1.01–7.07) 0.048
Model 3 17.3 (2.45–121) 0.004
HOMA-β Dec Model 1 1.79 (0.96–3.34) 0.07
Model 2 2.62 (1.08–6.33) 0.03
Model 3 22.7 (2.87–179) 0.003
Leptin Dec Model 1 0.76 (0.38–1.52) 0.43
Model 2 0.88 (0.38–2.03) 0.77
Model 3 2.45 (0.95–6.35) 0.06
TNFα Inc Model 1 1.54 (0.86–2.76) 0.15
Model 2 1.76 (0.86–3.61) 0.12
Model 3 1.57 (0.70–3.54) 0.27
Odds ratios for low serum amylase (< 60.0 U/ml) relative to normal-to-high
serum amylase (≥ 60 Uml) are shown for each 1-SD increase/decrease in the
clinical variables. All variables were log-transformed before analysis, except for
QUICKI, FPG, and HbA1c.
Model 1: unadjusted.
Model 2: adjusted for age, sex, smoking, daily alcohol consumption, regular
exercise, eGFR, systolic blood pressure, and high-density lipoprotein
cholesterol.
Model 3: Model 2 plus adjustment for BMI.
*Per 1-SD increase (Inc) or 1-SD decrease (Dec).
†Measured during a 75-g OGTT.
BMI: body mass index; FPG: fasting plasma glucose; FPI: fasting plasma insulin;
HOMA: homeostasis model assessment; OGTT: oral glucose tolerance test; PG:
plasma glucose; PI: plasma insulin; QUICKI: quantitative insulin sensitivity check
index; regular exercise: exercise over 30 minutes at least twice per week; TNF:
tumor necrosis factor.
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HOMA-β, and increased QUICKI in asymptomatic sub-
jects without advanced diabetes. Notably, the later asso-
ciations were not detected in earlier larger studies [3, 5].
However, as in the previous studies, BMI was the most
predominant factor explaining the serum amylase levels
in linear and nonlinear manners. It is particularly inter-
esting that adjustment for BMI and clinical confounders
was necessary to unveil these latent associations in the
multivariate logistic analysis. Indeed, this study revealed
that, after adjusting for BMI, serum amylase was posi-
tively correlated with HOMA-R and FPI, which is attrib-
utable to the strong correlation between HOMA-R and
FPI detected in this study. Since such high correla-
tions are commonly observed in non-diabetic indivi-
duals [16, 17], this finding is not contradictory.
Nonlinear associations between low serum amylase and
insulin resistance
The current results also showed complicated nonlinear
associations between low serum amylase and high
HOMA-R and high leptin (Figures 1 and 2), as low
serum amylase was associated with severe insulin resist-
ance but not moderate insulin resistance. A plausible ex-
planation is that high insulin secretion and/or severe
insulin resistance may cause insulin inactivity by down-
regulating insulin receptor expression or inhibiting insu-
lin signaling in certain cells, including pancreatic acinar
cells [18], eventually resulting in reduced insulinotropic
action on the acinar cells [19]. By contrast, light to mod-
erate insulin resistance is compensated for by increased
insulin secretion, or moderately increased insulin secre-
tion does not accompany insulin resistance, both of
which lead to increased insulinotropic action and pos-
sibly increased serum amylase. Consistently, a similar
nonlinear relationship was observed between serum
amylase and circulating leptin levels. Increased circulat-
ing leptin, a marker for leptin resistance, is thought to be
associated with insulin resistance [6, 7] and metabolic
syndrome [20].
It is noteworthy that similar nonlinear associations be-
tween serum amylase and HOMA-R and leptin were
observed in obese individuals (Figures 1B and 2B), Fur-
thermore, the significant difference in serum amylase be-
tween lean and obese subjects was particularly evident in
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Figure 1 A. Serum amylase levels according to HOMA-R. HOMA-R was classified as normal (< 1.6), moderate (1.6–2.5), or high (> 2.5). The
number of subjects in each group is shown under the bar. *Statistically significant difference between moderate and high HOMA-R (Bonferroni
test, P= 0.014). Bars represent standard errors. B Serum amylase levels according to HOMA-R and obesity. Subjects were divided into three groups
as in Figure 1A and then into lean (BMI<25 kg/m2) and obese (BMI≥ 25 kg/m2) groups. The number of subjects in each group is shown under
the bar. The difference between the lean and obese groups was of borderline significance (two-way ANOVA, P= 0.05). Bars represent standard
errors. C HOMA-R according to HOMA-R and obesity. Subjects were divided as in Figure 1A and B. The number of subjects in each group is
shown under the bar. HOMA-R was significantly different between lean and obese subjects in the high HOMA-R group (Mann–Whitney test,
P= 0.001). Bars represent standard errors. D Leptin levels according to HOMA-R and obesity. Subjects were divided as in Figure 1A and B. The
number of subjects in each group is shown under the bar. Bars represent standard errors.
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these were not significant (Figure 1B). Additionally,
HOMA-R and leptin were broadly similar between lean
and obese subjects in the normal leptin group and the
normal HOMA-R group (Figures 1C and D, 2C and D).
Then, although these trends should be confirmed in
large studies because of small sample sizes, these find-
ings suggest that other factors associated with high BMI,
but not insulin resistance, may also contribute to the
pathophysiology of low serum amylase in non-insulin-
resistant individuals. As we proposed in a recent article
[5], low serum amylase might reflect a physiological re-
sponse to over-nutrition with reduced food absorption to
regulate energy balance. Consistently, Kondo et al. [21]
showed that serum amylase was significantly lower in
obese subjects than in lean subjects and that low serum
amylase readily increased with diet therapy and weight
loss, which commonly accompanies the improvement of
insulin resistance, though. By contrast, the lower serum
amylase levels in lean and obese subjects in the high lep-
tin and high HOMA-R groups suggests that severeinsulin resistance exceeding a threshold level may predict
low serum amylase, independently of obesity. This might
be related with a previous finding that insulin resistance
can be associated with an increased risk of cardiovascu-
lar events independently of metabolic syndrome [22].Associations between low serum amylase and parameters
in the fasting state
The observed associations of low serum amylase with
HOMA-R, HOMA-β, PI at 0 and 60 min, but not with
PI at 120 min, suggest that low serum amylase may be
associated with low insulin action in the fasting state and
for up to 1 h after feeding, rather than the later post-
prandial state. This finding may help to explain the sig-
nificant association between serum amylase levels and
FPG, but not with HbA1c, that was observed in previous
large studies [3, 5]. HbA1c is an important marker for
overall circulating glucose levels, including the postpran-
dial state. In this study, serum amylase was not asso-
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Figure 2 A Serum amylase levels according to plasma leptin levels. Subjects were divided into three groups based on leptin levels: normal
(< 25 pg/ml), moderate (25–35 pg/ml), and high (> 35 pg/ml). The number of subjects in each group is shown under the bar. *Statistically
significant difference between moderate and high leptin (Bonferroni’s test, P= 0.013). Bars represent standard errors. B Serum amylase levels
according to leptin and obesity. Subjects were divided into three groups as in Figure 2A and then into lean (BMI<25 kg/m2) and obese
(BMI≥ 25 kg/m2) groups. The number of subjects in each group is shown under the bar. Leptin levels were significantly different between the
lean and obese groups (two-way ANOVA, P= 0.02). }Statistically significant difference between lean and obese subjects in the normal and
moderate leptin groups (Mann–Whitney test, both P<0.05). Bars represent standard errors. C HOMA-R according to leptin and obesity. Subjects
were divided as in Figure 2A and B. The number of subjects in each group is shown under the bar. HOMA-R was significantly different between
lean and obese subjects in the high leptin group (Mann–Whitney test, P= 0.004). Bars represent standard errors. D Leptin according to the leptin


















































21 10 23 14 7 6 4 11 12
Lean
Obese
Figure 3 A Serum amylase levels according to PI at 120 min during the OGTT. Subjects were divided into three groups based on PI at 120
as normal (≤ 40 mg/dl), moderate (40–50.5 mg/dl), and high (> 50.5 mg/dl). The number of subjects in each group is shown under the bar.
There were no significant differences among the three groups. Bars represent standard errors. B Serum amylase levels according to PI at 120 min
during the OGTT and obesity. Subjects were divided as in Figure 3A and then into lean (BMI<25 kg/m2) and obese (BMI≥ 25 kg/m2) groups. The
number of subjects in each group is shown under the bar. The difference in PI at 120 min between the lean and obese groups was of borderline
significance (two-way ANOVA, P= 0.06). Bars represent standard errors.
Muneyuki et al. Cardiovascular Diabetology 2012, 11:80 Page 7 of 9
http://www.cardiab.com/content/11/1/80
Muneyuki et al. Cardiovascular Diabetology 2012, 11:80 Page 8 of 9
http://www.cardiab.com/content/11/1/80[3, 5]. The lack of association between serum amylase
and FPG in this study may be attributable to the small
sample size.
Although TNFα was proposed as a candidate factor
explaining the low serum amylase levels, unexpectedly,
we found no significant association between low serum
amylase and high TNFα in this study. This might be at-
tributable to the small sample size and the specific char-
acteristics of our study population, including the small
proportions of subjects with overt diabetes, hypertension,
or dyslipidemia. Alternatively, central insulin or leptin
might be more effective on the serum levels of proin-
flammatory cytokines than systemic insulin or leptin, be-
cause a recent study by Burgos-Ramos et al. [23] showed
in animal study that intracerebroventricular administra-
tion of insulin and leptin remarkably reduced the serum
levels of TNFα.
Clinical relevance of low serum amylase
The clinical relevance of low serum amylase is still
poorly understood. In clinical practice, a deficiency of
pancreatic enzymes is known as pancreatic exocrine in-
sufficiency (PEI), which is characterized by steatorrhea,
malabsorption, and malnutrition [24, 25]. PEI is com-
monly observed in individuals with pancreatic diseases,
such as chronic pancreatitis and cystic fibrosis. However,
PEI defined as low levels of fecal elastase-1 was found in
approximately 50% of patients with type 1 diabetes and
20% of patients with type 2 diabetes [26, 27]. These, and
other results, indicate that low serum amylase may rep-
resent a close link between pancreatic endocrine dys-
function and exocrine dysfunction. Although it is
unknown whether low serum amylase fully reflects PEI,
it is possible that low serum amylase may be partially
related with pathogenesis of PEI considering that insulin
action is impaired in both type of diabetes. To fully elu-
cidate this issue, further studies focusing on endocrine
dysfunction and exocrine dysfunction are needed.
Limitations
Some limitations of this should be mentioned. First, the
sample size was small and the statistical power may be in-
sufficient to reliably assess associations, particularly when
the subjects were divided into sub-groups. Indeed, the large
odds ratios and wide 95% confidence intervals, especially
after adjustment for BMI, may be attributed to the small
sample size. Second, the associations between variables
were assessed in a cross-sectional manner, preventing us
from determining causality. Prospective longitudinal studies
and clinical trials are needed to evaluate the cause–effect re-
lationship. Third, insulin resistance was assessed by
HOMA-R, which is calculated from FPI and FPG. Ideally,
insulin resistance should be assessed using specific meth-
ods, such as the hyperinsulinemic–euglycemic clamp test[28] or the frequently sampled intravenous glucose toler-
ance test [29]. However, because of the complexity of these
tests, as well as their time-consuming procedures and ex-
pense, they were not performed in this study. It is also im-
portant to acknowledge that HOMA-R and QUICKI reflect
hepatic insulin resistance rather than peripheral insulin re-
sistance [30]. Thus, the current results should be inter-
preted with some caution. Finally, low serum amylase was
defined as serum amylase< 60 IU/l, based on the results of
an earlier large epidemiological study [3]. Different thresh-
olds for low serum amylase are likely to yield different
outcomes.
In conclusion, our results suggest a robust association
between low serum amylase and BMI, as well as latent
associations with decreased basal insulin and basal insu-
lin secretion, and with insulin resistance in a nonlinear
manner. These findings need to be confirmed in future
large studies.
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